146 related articles for article (PubMed ID: 16279768)
21. QSAR, docking, and CoMFA studies of GSK3 inhibitors.
García I; Fall Y; Gómez G
Curr Pharm Des; 2010; 16(24):2666-75. PubMed ID: 20642432
[TBL] [Abstract][Full Text] [Related]
22. Identification of the structural requirements of the receptor-binding affinity of diphenolic azoles to estrogen receptors alpha and beta by three-dimensional quantitative structure-activity relationship and structure-activity relationship analysis.
Demyttenaere-Kovatcheva A; Cronin MT; Benfenati E; Roncaglioni A; Lopiparo E
J Med Chem; 2005 Dec; 48(24):7628-36. PubMed ID: 16302803
[TBL] [Abstract][Full Text] [Related]
23. Combined 3D-QSAR modeling and molecular docking study on indolinone derivatives as inhibitors of 3-phosphoinositide-dependent protein kinase-1.
AbdulHameed MD; Hamza A; Liu J; Zhan CG
J Chem Inf Model; 2008 Sep; 48(9):1760-72. PubMed ID: 18717540
[TBL] [Abstract][Full Text] [Related]
24. Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic.
Medina M; Castro A
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):533-43. PubMed ID: 18600569
[TBL] [Abstract][Full Text] [Related]
25. Exploring the binding sites of glycogen synthase kinase 3. Identification and characterization of allosteric modulation cavities.
Palomo V; Soteras I; Perez DI; Perez C; Gil C; Campillo NE; Martinez A
J Med Chem; 2011 Dec; 54(24):8461-70. PubMed ID: 22050263
[TBL] [Abstract][Full Text] [Related]
26. Investigation of potential glycogen synthase kinase 3 inhibitors using pharmacophore mapping and virtual screening.
Dessalew N; Bharatam PV
Chem Biol Drug Des; 2006 Sep; 68(3):154-65. PubMed ID: 17062013
[TBL] [Abstract][Full Text] [Related]
27. Novel pyrazolopyrimidine derivatives as GSK-3 inhibitors.
Peat AJ; Boucheron JA; Dickerson SH; Garrido D; Mills W; Peckham J; Preugschat F; Smalley T; Schweiker SL; Wilson JR; Wang TY; Zhou HQ; Thomson SA
Bioorg Med Chem Lett; 2004 May; 14(9):2121-5. PubMed ID: 15080992
[TBL] [Abstract][Full Text] [Related]
28. Rational design based on bioactive conformation analysis of pyrimidinylbenzoates as acetohydroxyacid synthase inhibitors by integrating molecular docking, CoMFA, CoMSIA, and DFT calculations.
He YZ; Li YX; Zhu XL; Xi Z; Niu C; Wan J; Zhang L; Yang GF
J Chem Inf Model; 2007; 47(6):2335-44. PubMed ID: 17887745
[TBL] [Abstract][Full Text] [Related]
29. Insights into the structural requirements of farnesyltransferase inhibitors as potential anti-tumor agents based on 3D-QSAR CoMFA and CoMSIA models.
Puntambekar DS; Giridhar R; Yadav MR
Eur J Med Chem; 2008 Jan; 43(1):142-54. PubMed ID: 17448576
[TBL] [Abstract][Full Text] [Related]
30. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.
Zhang Q; Yang J; Liang K; Feng L; Li S; Wan J; Xu X; Yang G; Liu D; Yang S
J Chem Inf Model; 2008 Sep; 48(9):1802-12. PubMed ID: 18707092
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and in vitro characterization of 1-(4-aminofurazan-3-yl)-5-dialkylaminomethyl-1H-[1,2,3]triazole-4-carboxylic acid derivatives. A new class of selective GSK-3 inhibitors.
Olesen PH; Sørensen AR; Ursø B; Kurtzhals P; Bowler AN; Ehrbar U; Hansen BF
J Med Chem; 2003 Jul; 46(15):3333-41. PubMed ID: 12852764
[TBL] [Abstract][Full Text] [Related]
32. Exploration of a binding mode of benzothiazol-2-yl acetonitrile pyrimidine core based derivatives as potent c-Jun N-terminal kinase-3 inhibitors and 3D-QSAR analyses.
Sharma P; Ghoshal N
J Chem Inf Model; 2006; 46(4):1763-74. PubMed ID: 16859308
[TBL] [Abstract][Full Text] [Related]
33. Molecular modeling studies of N-substituted pyrrole derivatives--potential HIV-1 gp41 inhibitors.
Teixeira C; Barbault F; Rebehmed J; Liu K; Xie L; Lu H; Jiang S; Fan B; Maurel F
Bioorg Med Chem; 2008 Mar; 16(6):3039-48. PubMed ID: 18226912
[TBL] [Abstract][Full Text] [Related]
34. 3D-QSAR studies of farnesyltransferase inhibitors: a comparative molecular field analysis approach.
Puntambekar D; Giridhar R; Yadav MR
Bioorg Med Chem Lett; 2006 Apr; 16(7):1821-7. PubMed ID: 16455255
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and evaluation of novel heterocyclic inhibitors of GSK-3.
Smalley TL; Peat AJ; Boucheron JA; Dickerson S; Garrido D; Preugschat F; Schweiker SL; Thomson SA; Wang TY
Bioorg Med Chem Lett; 2006 Apr; 16(8):2091-4. PubMed ID: 16460937
[TBL] [Abstract][Full Text] [Related]
36. 3D QSAR CoMFA/CoMSIA, molecular docking and molecular dynamics studies of fullerene-based HIV-1 PR inhibitors.
Durdagi S; Mavromoustakos T; Papadopoulos MG
Bioorg Med Chem Lett; 2008 Dec; 18(23):6283-9. PubMed ID: 18951793
[TBL] [Abstract][Full Text] [Related]
37. Molecular docking and three-dimensional quantitative structure-activity relationship studies on the binding modes of herbicidal 1-(substituted phenoxyacetoxy)alkylphosphonates to the E1 component of pyruvate dehydrogenase.
Peng H; Wang T; Xie P; Chen T; He HW; Wan J
J Agric Food Chem; 2007 Mar; 55(5):1871-80. PubMed ID: 17288442
[TBL] [Abstract][Full Text] [Related]
38. 3D-QSAR and docking studies of aminopyridine carboxamide inhibitors of c-Jun N-terminal kinase-1.
Yi P; Qiu M
Eur J Med Chem; 2008 Mar; 43(3):604-13. PubMed ID: 17602798
[TBL] [Abstract][Full Text] [Related]
39. Glycogen synthase kinase 3 inhibition protects the heart from acute ischemia-reperfusion injury via inhibition of inflammation and apoptosis.
Gao HK; Yin Z; Zhou N; Feng XY; Gao F; Wang HC
J Cardiovasc Pharmacol; 2008 Sep; 52(3):286-92. PubMed ID: 18806610
[TBL] [Abstract][Full Text] [Related]
40. Receptor-based 3D-QSAR studies of checkpoint Wee1 kinase inhibitors.
Wichapong K; Lindner M; Pianwanit S; Kokpol S; Sippl W
Eur J Med Chem; 2009 Apr; 44(4):1383-95. PubMed ID: 18976834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
